Drug Profile
Calcitriol - Roche
Alternative Names: Dihydroxycholecalciferol - Roche; Dihydroxyvitamin D3 - Roche; RO 215535; RocaltrolLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Roche
- Developer Chugai Pharmaceutical; Kirin Holdings Company; Roche; Roche Canada; Roche Wien
- Class Antipsoriatics; Chemoprotectants; Dihydroxycholecalciferols; Osteoporosis therapies; Small molecules; Vitamin D analogues
- Mechanism of Action Vitamin D3 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Calcium metabolism disorders; Hypocalcaemia; Hypoparathyroidism; Hypophosphataemia; Osteodystrophy; Osteomalacia; Postmenopausal osteoporosis; Rickets; Secondary hyperparathyroidism; Vitamin D deficiency
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer in USA (SC)
- 16 Jun 2008 Fontus Pharmaceuticals acquires Calcitriol from Roche
- 30 Oct 2002 Nippon Roche has been merged into Chugai Pharmaceutical